Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NivoMela adjuvant nivolumab in high-risk stage II melanoma
2023-509394-23-00Phase 3Authorised
- Sponsor
- Universitätsmedizin Essen
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of nivolumab in melanoma (2 arms), sponsored by Universitätsmedizin Essen. Primary endpoint: Relapse / recurrence-free survival. Planned start Jun 2020; status: authorised.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2023-509394-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509394-23-00.